EyeGene Inc is a Korea-based company primarily engaged in research and development in the medical and pharmaceutical fields. The Company is mainly engaged in the research and development of messenger ribonucleic acid (mRNA)-based vaccines. The Company also develops novel treatments for ophthalmic diseases, including treatments for macular degeneration and diabetic retinopathy, as well as adeno-associated virus (AAV) gene therapy targeting rare retinal diseases. In addition, the Company develops a quadrivalent meningococcal vaccine and recombinant botulinum toxin.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
14/08/26	KRW 2,015.00	-0.74%	171,592
13/08/26	KRW 2,030.00	+3.05%	579,399
12/08/26	KRW 1,970.00	+1.03%	257,278
11/08/26	KRW 1,950.00	+6.97%	322,118

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 14/08/2026			5-day change	1st Jan Change
2,015.00 ^KRW	-0.74%		+20.30%	+15.87%

16/09/25	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE
21/12/23	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI

Market Cap	87.11B 61.59M 53.22M 49.91M 45.47M 85.45M 5.88B 86.67M 586M 229M 2.95B 231M 226M 9.84B	P/E 2024	-5.71x	P/E 2025	-3.1x
Enterprise Value	42.17B 29.82M 25.77M 24.16M 22.01M 41.37M 2.85B 41.96M 284M 111M 1.43B 112M 109M 4.76B	EV / Sales 2024	11.6x	EV / Sales 2025	8.48x
Free-Float	70.86%	Yield 2024 *	-	Yield 2025	-

16/09/25	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE
21/12/23	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
13/12/23	EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
15/05/23	EyeGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
15/03/23	EyeGene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
07/04/22	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
05/10/21	Maravai LifeSciences : Says Unit TriLink To Supply Proprietary Technology to EyeGene for Production of COVID-19 Vaccine	MT
20/09/21	EyeGene Inc.(KOSDAQ:A185490) added to S&P Global BMI Index	CI
18/09/20	EyeGene Inc. announced that it has received KRW 22 billion in funding from a group of investors	CI
16/09/20	EyeGene Inc. announced that it expects to receive KRW 22 billion in funding from a group of investors	CI
23/09/19	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
28/09/18	EyeGene Inc. announced that it has received KRW 29.9998664 billion in funding from Meritz Securities Co., Ltd., Investment Arm, IBK Capital Corporation, Korea Investment & Securities Co., Ltd., Investment Arm	CI
20/09/18	EyeGene Inc. announced that it expects to receive KRW 29.9998664 billion in funding from a group of investors	CI

1 day	-0.74%
1 week	+20.30%
Current month	+37.17%
1 month	+35.14%
3 months	+39.06%
6 months	+40.22%
Current year	+15.87%

EyeGene Inc. Stock

Stocks

A185490

KR7185490000

Pharmaceuticals

Valuation: EyeGene Inc.

Chart: EyeGene Inc.

Latest news : EyeGene Inc.

Quotes and Performance

Course Extremes

Managers and Directors: EyeGene Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,800	2,200
1 month	1,393	2,200
Current year	1,182	2,805
1 year	1,182	3,180
3 years	1,182	4,895
5 years	1,182	60,200
10 years	1,182	60,200

Manager	Title	Age	Since
Suk-Keun Choi CEO	Chief Executive Officer	59	20/02/2024
Myeong-Jae Lee DFI	Director of Finance/CFO	56	01/05/2012
Won-Il Yoo PSD	President	63	23/06/2000

Director	Title	Age	Since
Won-Il Yoo BRD	Director/Board Member	63	23/06/2000
Myeong-Jae Lee BRD	Director/Board Member	56	20/02/2024
Dal-Hyun Kim BRD	Director/Board Member	64	13/05/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/4/24	Kwang-In Lee	Buy		8,019	0.0297%
10/4/24	Kwang-In Lee	Buy		12,297	0.0455%
12/3/24	Won-Il Yoo	Buy	Chairperson	1,000	0.0037%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EYEGENE INC.	-0.74%	+20.30%	-35.31%	-45.54%	61.62M
ELI LILLY AND COMPANY	+0.25%	-0.22%	+68.73%	+116.60%	1,052B
JOHNSON & JOHNSON	+0.78%	+1.21%	+48.53%	+52.20%	627B
ABBVIE INC.	+0.35%	+1.74%	+21.11%	+65.18%	441B
ROCHE HOLDING AG	+0.28%	-3.05%	+39.10%	+36.65%	349B
NOVARTIS AG	+0.78%	-2.05%	+24.03%	+36.97%	287B
ASTRAZENECA PLC	+0.87%	-2.82%	-0.28%	+6.27%	241B
AMGEN INC.	+1.00%	+2.05%	+41.46%	+58.24%	224B
NOVO NORDISK A/S	-0.78%	-4.16%	-10.28%	-53.87%	202B
GILEAD SCIENCES, INC.	+0.40%	+4.29%	+17.36%	+78.10%	172B
Average	+0.32%	+0.36%	+21.45%	+35.08%	359.52B
Weighted average by Cap.	+0.44%	-0.63%	+39.71%	+62.49%

	2024	2025
Net sales	3.36B 2.37M 2.05M 1.92M 1.75M 3.29M 227M 3.34M 22.57M 8.84M 114M 8.9M 8.71M 379M	3.57B 2.52M 2.18M 2.04M 1.86M 3.5M 241M 3.55M 23.99M 9.39M 121M 9.46M 9.26M 403M
Net income	-12.13B -8.57M -7.41M -6.95M -6.33M -11.9M -819M -12.07M -81.56M -31.93M -410M -32.16M -31.47M -1.37B	-15.71B -11.1M -9.6M -9M -8.2M -15.41M -1.06B -15.63M -106M -41.35M -531M -41.65M -40.76M -1.77B
Net Debt	-30.11B -21.29M -18.4M -17.25M -15.72M -29.53M -2.03B -29.96M -202M -79.27M -1.02B -79.84M -78.13M -3.4B	-44.94B -31.77M -27.46M -25.75M -23.46M -44.08M -3.03B -44.71M -302M -118M -1.52B -119M -117M -5.08B